Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Macron visits Marseille doctor working on COVID-19 drug touted by Trump

Published 04/09/2020, 03:02 PM
Updated 04/09/2020, 03:35 PM
© Reuters. FILE PHOTO: Spread of the coronavirus disease (COVID-19) in La Courneuve near Paris

PARIS (Reuters) - President Emmanuel Macron visited a French doctor in Marseille on Thursday whose work on an anti-malaria drug has been promoted by U.S. President Donald Trump as a potential weapon against COVID-19 but has split medical opinion.

Macron, who met Professor Didier Raoult at his Marseille hospital behind closed doors, did not endorse the treatment, his office said, adding that it was too early for the French government to assess its effectiveness.

"One visit does not legitimate a scientific protocol, a visit simply marks the head of state's interest for these clinical trials, whether they are promising or not," a presidential adviser said.

But the presidential visit is a boost for the Marseille professor, who has become one of France's best-known doctors after his treatment was cited in a tweet by Trump, calling it "one of the biggest game-changers in the history of medicine".

His research team has published data showing that out of 80 mild COVID-19 patients treated with hydroxychloroquine and azithromycin, 93 percent had no detectable levels of the virus after eight days.

Doctors have questioned the value of the Marseille study and several papers from China on the same treatment as being too small or poorly designed to offer hard evidence of benefit.

Most do not compare outcomes of patients who received the malaria therapies with people who did not, considered the most reliable measure of a drug's effectiveness.

Last week, doctors in Paris reported that they tried to replicate the results of the Marseille study and failed.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

According to Les Echos newspaper, Raoult gave Macron the results of a new study on 1,061 patients showing a 91 percent success rate.

Asked about the report, the presidential adviser said Macron had taken note of a certain number of elements presented by the professor and would give it careful consideration, in particular at a meeting with his scientific advisory panel.

France, which has entered its fourth week of a lockdown imposed to slow the coronavirus outbreak, has reported a total death toll of 12,210 people as of Thursday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.